Figure 4
Figure 4. Role of FXa in vascular inflammation in SCD. (A-F) PT (A) and plasma levels of TAT (B), sVCAM-1 (C), IL-6 (D), and MPO (E) in the lungs and average number of neutrophils (F) in lungs of BERKAA (n = 16) and BERKSS (n = 13-15) mice fed with chow containing rivaroxaban (Riv) or placebo control (Con) for 10 days. Asterisks directly above bars indicate statistical significance between BERKSS mice compared with BERKAA mice within the same treatment group (Con or Riv) (*P < .05, **P < .01, ***P < .001).

Role of FXa in vascular inflammation in SCD. (A-F) PT (A) and plasma levels of TAT (B), sVCAM-1 (C), IL-6 (D), and MPO (E) in the lungs and average number of neutrophils (F) in lungs of BERKAA (n = 16) and BERKSS (n = 13-15) mice fed with chow containing rivaroxaban (Riv) or placebo control (Con) for 10 days. Asterisks directly above bars indicate statistical significance between BERKSS mice compared with BERKAA mice within the same treatment group (Con or Riv) (*P < .05, **P < .01, ***P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal